Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, et al. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013 Oct 1;2(10):e26097.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009 Aug;9(8):568–580.
   PubMed Web of Science ®Google Scholar
• Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005 Aug 25;436(7054):1186–1190.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Simonetta F, Baker J, et al. Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. JCI Insight. 2019 Jun 18;5(14):e127729.
   Google Scholar
• Jung H, Hsiung B, Pestal K, et al. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med. 2012 Dec 17;209(13):2409–2422.
   PubMed Web of Science ®Google Scholar
• Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol. 2018;9:2040.
   PubMed Web of Science ®Google Scholar
• Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012 Jan 15;72(2):460–471.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879–6884.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413–441.
   PubMed Web of Science ®Google Scholar
• Upshaw JL, Leibson PJ. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol. 2006 Jun;18(3):167–175.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11521–11526.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001 Sep 13;413(6852):165–171.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008 Oct 6;27(45):5932–5943.
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999 Jul 30;285(5428):727–729.
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Miyake S, Yamamura T, et al. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002 Mar 4;195(5):625–636.
   PubMed Web of Science ®Google Scholar
• Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol. 2003 Apr;3(4):304–316.
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999 Jul 30;285(5428):730–732.
   PubMed Web of Science ®Google Scholar
• Li P, Morris DL, Willcox BE, et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol. 2001 May;2(5):443–451.
   PubMed Web of Science ®Google Scholar
• Garrity D, Call ME, Feng J, et al. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7641–7646.
   PubMed Web of Science ®Google Scholar
• Andre P, Castriconi R, Espeli M, et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol. 2004 Apr;34(4):961–971.
   PubMed Web of Science ®Google Scholar
• Bryceson YT, March ME, Ljunggren HG, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006 Jan 1;107(1):159–166.
   PubMed Web of Science ®Google Scholar
• Groh V, Steinle A, Bauer S, et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science. 1998 Mar 13;279(5357):1737–1740.
   PubMed Web of Science ®Google Scholar
• Maasho K, Opoku-Anane J, Marusina AI, et al. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol. 2005 Apr 15;174(8):4480–4484.
   PubMed Web of Science ®Google Scholar
• Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001 Nov 15;167(10):5527–5530.
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity. 2004 Sep;21(3):357–366.
   PubMed Web of Science ®Google Scholar
• Park YP, Choi SC, Kiesler P, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gammac cytokines and TGF-beta1. Blood. 2011 Sep 15;118(11):3019–3027.
   PubMed Web of Science ®Google Scholar
• Burgess SJ, Marusina AI, Pathmanathan I, et al. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol. 2006 Feb 1;176(3):1490–1497.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120–4125.
   PubMed Web of Science ®Google Scholar
• Muntasell A, Magri G, Pende D, et al. Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood. 2010 Jun 24;115(25):5170–5179.
   PubMed Web of Science ®Google Scholar
• Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12445–12450.
   PubMed Web of Science ®Google Scholar
• Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001 May-Jun;53(4):279–287.
   PubMed Web of Science ®Google Scholar
• Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015 Jun;3(6):575–582.
   PubMed Web of Science ®Google Scholar
• Radaev S, Rostro B, Brooks AG, et al. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity. 2001 Dec;15(6):1039–1049.
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001 Feb;14(2):123–133.
   PubMed Web of Science ®Google Scholar
• Bacon L, Eagle RA, Meyer M, et al. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 2004 Jul 15;173(2):1078–1084.
   PubMed Web of Science ®Google Scholar
• Eagle RA, Traherne JA, Hair JR, et al. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol. 2009 Nov;39(11):3207–3216.
   PubMed Web of Science ®Google Scholar
• Wittenbrink M, Spreu J, Steinle A. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain. Eur J Immunol. 2009 Jun;39(6):1642–1651.
   PubMed Web of Science ®Google Scholar
• Carapito R, Bahram S. Genetics, genomics, and evolutionary biology of NKG2D ligands. Immunol Rev. 2015 Sep;267(1):88–116.
   PubMed Web of Science ®Google Scholar
• Zoller T, Wittenbrink M, Hoffmeister M, et al. Cutting an NKG2D ligand short: cellular processing of the peculiar human NKG2D ligand ULBP4. Front Immunol. 2018;9:620.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M. The impact of glycosyl-phosphatidyl-inositol anchored MICA alleles on novel NKG2D-based therapies. Front Immunol. 2015;6:193.
   PubMed Web of Science ®Google Scholar
• Schrambach S, Ardizzone M, Leymarie V, et al. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One. 2007 Jun 13;2(6):e518.
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002 Nov 1;62(21):6178–6186.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Randolph-Habecker J, et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001 Mar;2(3):255–260.
   PubMed Web of Science ®Google Scholar
• Welte SA, Sinzger C, Lutz SZ, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003 Jan;33(1):194–203.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol. 2002 Jun;14(3):306–311.
   PubMed Web of Science ®Google Scholar
• Trembath AP, Markiewicz MA. More than decoration: roles for natural killer group 2 member d ligand expression by immune cells. Front Immunol. 2018;9:231.
   PubMed Web of Science ®Google Scholar
• Cerboni C, Zingoni A, Cippitelli M, et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood. 2007 Jul 15;110(2):606–615.
   PubMed Web of Science ®Google Scholar
• Molinero LL, Fuertes MB, Rabinovich GA, et al. Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol. 2002 May;71(5):791–797.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol. 2003 Nov 15;171(10):5423–5429.
   PubMed Web of Science ®Google Scholar
• Hamerman JA, Ogasawara K, Lanier LL. Cutting edge: toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol. 2004 Feb 15;172(4):2001–2005.
   PubMed Web of Science ®Google Scholar
• Kloss M, Decker P, Baltz KM, et al. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol. 2008 Nov 15;181(10):6711–6719.
   PubMed Web of Science ®Google Scholar
• Wiemann K, Mittrucker HW, Feger U, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol. 2005 Jul 15;175(2):720–729.
   PubMed Web of Science ®Google Scholar
• Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003 Dec 15;63(24):8996–9006.
   PubMed Web of Science ®Google Scholar
• Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008 Apr;28(4):571–580.
   PubMed Web of Science ®Google Scholar
• Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005 Sep;6(9):928–937.
   PubMed Web of Science ®Google Scholar
• Jelencic V, Sestan M, Kavazovic I, et al. NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development. Nat Immunol. 2018 Oct;19(10):1083–1092.
   PubMed Web of Science ®Google Scholar
• Sheppard S, Guedes J, Mroz A, et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat Commun. 2017 Jan 27;8:13930.
   PubMed Web of Science ®Google Scholar
• Codo P, Weller M, Meister G, et al. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014 Sep 15;5(17):7651–7662.
   PubMed Web of Science ®Google Scholar
• Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006 Sep;129(Pt 9):2416–2425.
   PubMedGoogle Scholar
• Baragano Raneros A, Martin-Palanco V, Fernandez AF, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015 Jan-Feb;16(1):71–82.
   PubMed Web of Science ®Google Scholar
• Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002 Oct 15;169(8):4098–4102.
   PubMed Web of Science ®Google Scholar
• Chitadze G, Lettau M, Bhat J, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer. 2013 Oct 1;133(7):1557–1566.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006 Mar 1;66(5):2520–2526.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008 Aug 1;68(15):6368–6376.
   PubMed Web of Science ®Google Scholar
• Liu G, Atteridge CL, Wang X, et al. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol. 2010 Apr 1;184(7):3346–3350.
   PubMed Web of Science ®Google Scholar
• Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol. 2006 Mar;67(3):188–195.
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002 Oct 17;419(6908):734–738.
   PubMed Web of Science ®Google Scholar
• Deng W, Gowen BG, Zhang L, et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science. 2015 Apr 3;348(6230):136–139.
   PubMedGoogle Scholar
• Ashiru O, Boutet P, Fernandez-Messina L, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010 Jan 15;70(2):481–489.
   PubMed Web of Science ®Google Scholar
• Ashiru O, Lopez-Cobo S, Fernandez-Messina L, et al. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem J. 2013 Sep 1;454(2):295–302.
   PubMedGoogle Scholar
• Fernandez-Messina L, Ashiru O, Boutet P, et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 2010 Mar 19;285(12):8543–8551.
   PubMed Web of Science ®Google Scholar
• von Strandmann EP, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006 Mar 1;107(5):1955–1962.
   PubMed Web of Science ®Google Scholar
• Rothe A, Jachimowicz RD, Borchmann S, et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014 Jun 15;134(12):2829–2840.
   PubMed Web of Science ®Google Scholar
• Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol Res. 2018 Jul;6(7):776–787.
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013 Oct;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 2011 Mar 15;71(6):2066–2076.
   PubMed Web of Science ®Google Scholar
• Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, et al. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Int J Cancer. 2015 Mar 1;136(5):1073–1084.
   PubMed Web of Science ®Google Scholar
• Raab S, Steinbacher J, Schmiedel BJ, et al. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J Immunol. 2014 Oct 15;193(8):4261–4272.
   PubMed Web of Science ®Google Scholar
• Ghasemi R, Lazear E, Wang X, et al. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun. 2016 Sep 21;7:12878.
   PubMed Web of Science ®Google Scholar
• Krieg S, Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol. 2012;3:388.
   PubMed Web of Science ®Google Scholar
• Zingoni A, Fionda C, Borrelli C, et al. Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol. 2017;8:1194.
   PubMed Web of Science ®Google Scholar
• Ferrari de Andrade L, Kumar S, Luoma AM, et al. Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells. Cancer Immunol Res. 2020 Mar 24. DOI:10.1158/2326-6066.CIR-19-0483.
   PubMed Web of Science ®Google Scholar
• Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005 Jul 15;65(14):6321–6329.
   PubMed Web of Science ®Google Scholar
• Butler JE, Moore MB, Presnell SR, et al. Proteasome regulation of ULBP1 transcription. J Immunol. 2009 May 15;182(10):6600–6609.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M, Chisholm SE, Cassady-Cain RL, et al. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008 Mar 1;68(5):1546–1554.
   PubMed Web of Science ®Google Scholar
• Armeanu S, Krusch M, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 1;14(11):3520–3528.
   PubMed Web of Science ®Google Scholar
• Lazarova M, Steinle A. Impairment of NKG2D-mediated tumor immunity by TGF-beta. Front Immunol. 2019;10:2689.
   PubMed Web of Science ®Google Scholar
• Lazarova M, Steinle A. The NKG2D axis: an emerging target in cancer immunotherapy. Expert Opin Ther Targets. 2019 Apr;23(4):281–294.
   PubMed Web of Science ®Google Scholar
• Frazao A, Rethacker L, Messaoudene M, et al. NKG2D/NKG2-ligand pathway offers new opportunities in cancer treatment. Front Immunol. 2019;10:661.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720–724.
   PubMed Web of Science ®Google Scholar
• Brocker T, Peter A, Traunecker A, et al. New simplified molecular design for functional T cell receptor. Eur J Immunol. 1993 Jul;23(7):1435–1439.
   PubMed Web of Science ®Google Scholar
• Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4318–4322.
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002 Aug 15;100(4):1265–1273.
   PubMed Web of Science ®Google Scholar
• Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res. 2009 Aug 1;15(15):4857–4866.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013 Apr;3(4):388–398.
   PubMed Web of Science ®Google Scholar
• Topfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015 Apr 1;194(7):3201–3212.
   PubMed Web of Science ®Google Scholar
• Li Y, Hermanson DL, Moriarity BS, et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018 Aug 2;23(2):181–192 e5.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361–1365.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Springuel L, Lonez C, Alexandre B, et al. Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies. BioDrugs. 2019 Oct;33(5):515–537.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005 Sep 1;106(5):1544–1551.
   PubMed Web of Science ®Google Scholar
• Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 2007 Nov 15;67(22):11029–11036.
   PubMed Web of Science ®Google Scholar
• Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
   PubMedGoogle Scholar
• Lehner M, Gotz G, Proff J, et al. Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One. 2012;7(2):e31210.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Santoro S, et al. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013 Mar;24(3):295–305.
   PubMed Web of Science ®Google Scholar
• Deng X, Gao F, Li N, et al. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. Am J Cancer Res. 2019;9(5):945–958.
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, et al. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018 Feb 15;78(4):1031–1043.
   PubMed Web of Science ®Google Scholar
• Murad JM, Baumeister SH, Werner L, et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 2018 Jul;20(7):952–963.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Rynda-Apple A, et al. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. J Immunol. 2012 Jun 15;188(12):6389–6398.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2013 Apr 1;2(4):e23564.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol. 2013 Mar 1;190(5):2455–2463.
   PubMed Web of Science ®Google Scholar
• Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009 Dec 1;183(11):6939–6947.
   PubMed Web of Science ®Google Scholar
• VanSeggelen H, Hammill JA, Dvorkin-Gheva A, et al. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther. 2015 Oct;23(10):1600–1610.
   PubMed Web of Science ®Google Scholar
• Sentman ML, Murad JM, Cook WJ, et al. Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J Immunol. 2016 Dec 15;197(12):4674–4685.
   PubMed Web of Science ®Google Scholar
• Godbersen-Palmer C, Coupet TA, Grada Z, et al. Toxicity induced by a bispecific T cell-redirecting protein is mediated by both T cells and myeloid cells in immunocompetent mice. J Immunol. 2020 Apr 15. DOI:10.4049/jimmunol.1901401.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Brayer J, Sagatys EM, et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018 Sep;103(9):e424–e426.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Murad J, Werner L, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res. 2019 Jan;7(1):100–112.
   PubMed Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013 Mar 15;73(6):1777–1786.
   PubMed Web of Science ®Google Scholar
• Parihar R, Rivas C, Huynh M, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019 Mar;7(3):363–375.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019 Jun 5;27(6):1114–1125.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 2006 Dec;55(12):1584–1589.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases. Int J Cancer. 2006 Feb 1;118(3):684–687.
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003 Aug 15;102(4):1389–1396.
   PubMed Web of Science ®Google Scholar
• Hilpert J, Grosse-Hovest L, Grunebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012 Aug 1;189(3):1360–1371.
   PubMed Web of Science ®Google Scholar
• Weil S, Memmer S, Lechner A, et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol. 2017;8:387.
   PubMed Web of Science ®Google Scholar
• Ferrari de Andrade L, Tay RE, Pan D, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018 Mar 30;359(6383):1537–1542.
   PubMed Web of Science ®Google Scholar
• Steinle A, Groh V, Spies T. Diversification, expression, and gamma delta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12510–12515.
   PubMed Web of Science ®Google Scholar
• Bahram S, Bresnahan M, Geraghty DE, et al. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6259–6263.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killers join the fight against cancer. Science. 2018 Mar 30;359(6383):1460–1461.
   PubMed Web of Science ®Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010 May;235(1):267–285.
   PubMed Web of Science ®Google Scholar
• Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood. 2005 Sep 1;106(5):1711–1717.
   PubMed Web of Science ®Google Scholar
• https://www.cullinanoncology.com/2020/06/11/cullinan-26m-series-a-financing/
   Google Scholar
• Lonez C, Verma B, Hendlisz A, et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017 Nov 12;7(11):e017075.
   PubMed Web of Science ®Google Scholar